Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO. 2 TO FORM S-1 - Unicycive Therapeutics, Inc. | ea142731-s1a2_unicycivethera.htm |
| EX-5.1 - OPINION OF SHEPPARD, MULLIN, RICHTER & HAMPTON LLP - Unicycive Therapeutics, Inc. | ea142731ex5-1_unicycive.htm |
| EX-4.3 - FORM OF UNDERWRITER'S UNIT PURCHASE OPTION - Unicycive Therapeutics, Inc. | ea142731ex4-3_unicycive.htm |
| EX-4.2 - FORM OF WARRANT AGENT AGREEMENT - Unicycive Therapeutics, Inc. | ea142731ex4-2_unicycive.htm |
| EX-3.5 - AMENDED AND RESTATED BYLAWS - Unicycive Therapeutics, Inc. | ea142731ex3-5_unicycive.htm |
| EX-3.4 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Unicycive Therapeutics, Inc. | ea142731ex3-4_unicycive.htm |
| EX-1.1 - FORM OF UNDERWRITING AGREEMENT - Unicycive Therapeutics, Inc. | ea142731ex1-1_unicycive.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in Amendment No. 2 to this Registration Statement on Form S-1 of our report dated February 18, 2021 (except for the effects of the stock split as described in Note 2, as to which the date is June 21, 2021), with respect to the financial statements of Unicycive Therapeutics, Inc. as of December 31, 2020 and 2019, and for the years then ended (which includes an explanatory paragraph related to the existence of substantial doubt about the Company’s ability to continue as a going concern), and to the reference to us under the heading “Experts” included in this Registration Statement and accompanying prospectus on Form S-1.
| /s/ Mayer Hoffman McCann P.C. | |
| San Diego, California | |
| June 21, 2021 |